Diana Cirstea

4.4k total citations · 1 hit paper
80 papers, 2.4k citations indexed

About

Diana Cirstea is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Diana Cirstea has authored 80 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Hematology, 43 papers in Molecular Biology and 38 papers in Oncology. Recurrent topics in Diana Cirstea's work include Multiple Myeloma Research and Treatments (60 papers), Protein Degradation and Inhibitors (21 papers) and Peptidase Inhibition and Analysis (15 papers). Diana Cirstea is often cited by papers focused on Multiple Myeloma Research and Treatments (60 papers), Protein Degradation and Inhibitors (21 papers) and Peptidase Inhibition and Analysis (15 papers). Diana Cirstea collaborates with scholars based in United States, Japan and United Kingdom. Diana Cirstea's co-authors include Noopur Raje, Teru Hideshima, Kenneth C. Anderson, Nikhil C. Munshi, Güllü Görgün, Loredana Santo, Homare Eda, Paul G. Richardson, Yiguo Hu and Sonia Vallet and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Diana Cirstea

78 papers receiving 2.4k citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

2012 488 citations Loredana Santo, Teru Hideshima et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Diana Cirstea United States	22	1.6k	1.1k	894	290	210	80	2.4k
Giulia Perrone Italy	20	1.3k 0.8×	1.2k 1.1×	1.5k 1.7×	196 0.7×	207 1.0×	53	2.4k
Mohit Trikha United States	29	1.2k 0.7×	930 0.8×	574 0.6×	136 0.5×	129 0.6×	55	2.5k
Michaël Sébag Canada	23	1.0k 0.6×	766 0.7×	801 0.9×	88 0.3×	199 0.9×	115	1.8k
Matthew Squires United States	25	1.1k 0.7×	825 0.8×	220 0.2×	262 0.9×	181 0.9×	71	1.9k
Concetta Conticello Italy	24	1.4k 0.9×	1.7k 1.5×	649 0.7×	192 0.7×	218 1.0×	91	3.0k
Véronique Mansat‐De Mas France	25	1.3k 0.8×	428 0.4×	1.4k 1.6×	109 0.4×	141 0.7×	57	2.5k
Nicolas Chapuis France	26	1.8k 1.1×	466 0.4×	970 1.1×	66 0.2×	207 1.0×	74	2.7k
Kenneth H. Shain United States	26	1.7k 1.0×	1.7k 1.5×	1.2k 1.4×	121 0.4×	429 2.0×	144	3.4k
Elie Traer United States	21	1.1k 0.7×	353 0.3×	666 0.7×	93 0.3×	67 0.3×	64	1.8k
Mei Dong China	18	1.2k 0.8×	539 0.5×	167 0.2×	106 0.4×	159 0.8×	36	1.7k

Countries citing papers authored by Diana Cirstea

Since Specialization

Citations

This map shows the geographic impact of Diana Cirstea's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diana Cirstea with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diana Cirstea more than expected).

Fields of papers citing papers by Diana Cirstea

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Diana Cirstea. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diana Cirstea. The network helps show where Diana Cirstea may publish in the future.

Co-authorship network of co-authors of Diana Cirstea

This figure shows the co-authorship network connecting the top 25 collaborators of Diana Cirstea. A scholar is included among the top collaborators of Diana Cirstea based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diana Cirstea. Diana Cirstea is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Little, Jessica S, Andrew J. Yee, Omar Nadeem, et al.. (2025). Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy. Blood Advances. 9(16). 4190–4194. 1 indexed citations

Choa, Ruth, Kevin C. Miller, Samuel Han, et al.. (2025). Impact of body mass index on anti-BCMA chimeric antigen receptor T-cell therapy outcomes in multiple myeloma. 1(3). 100015–100015.

Banerjee, Rahul, Meera Mohan, Kai Rejeski, et al.. (2025). Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels. Blood Advances. 9(18). 4720–4726. 2 indexed citations

Han, Samuel, Andrew R. Branagan, Elizabeth O’Donnell, et al.. (2025). Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury. Blood Advances. 9(13). 3129–3135. 2 indexed citations

Gustine, Joshua, Andrew R. Branagan, Diana Cirstea, et al.. (2025). Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myeloma. Blood Advances. 9(12). 3026–3030. 1 indexed citations

Nakamoto-Matsubara, Rie, Valentina Nardi, Nora Horick, et al.. (2024). Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma. Blood Cancer Journal. 14(1). 224–224. 2 indexed citations

Gustine, Joshua, Andrew R. Branagan, Diana Cirstea, et al.. (2024). OA-06 Impact of Clonal Hematopoiesis on Clinical Outcomes to BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24. S4–S5. 1 indexed citations

O’Donnell, Elizabeth, Clifton C. Mo, Andrew J. Yee, et al.. (2023). A Phase II Study of Isatuximab, Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial). Blood. 142(Supplement 1). 4671–4671. 2 indexed citations

Fillmore, Nathanael R., Clark DuMontier, Jennifer La, et al.. (2021). Defining Multimorbidity and Its Impact in Older United States Veterans Newly Treated for Multiple Myeloma. JNCI Journal of the National Cancer Institute. 113(8). 1084–1093. 11 indexed citations

10.

DuMontier, Clark, Nathanael R. Fillmore, Cenk Yildirim, et al.. (2021). Contemporary Analysis of Electronic Frailty Measurement in Older Adults with Multiple Myeloma Treated in the National US Veterans Affairs Healthcare System. Cancers. 13(12). 3053–3053. 18 indexed citations

11.

Eda, Homare, Loredana Santo, Marc N. Wein, et al.. (2016). Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease. Journal of Bone and Mineral Research. 31(6). 1225–1234. 77 indexed citations

12.

Suzuki, Rikio, Shohei Kikuchi, Takeshi Harada, et al.. (2015). Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells. PLoS ONE. 10(12). e0143847–e0143847. 19 indexed citations

13.

Cirstea, Diana, Loredana Santo, Teru Hideshima, et al.. (2014). Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma. Molecular Cancer Therapeutics. 13(11). 2489–2500. 24 indexed citations

14.

Mimura, Naoya, Teru Hideshima, Toshiyasu Shimomura, et al.. (2014). Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition. Cancer Research. 74(16). 4458–4469. 66 indexed citations

15.

Fabre, Claire, Naoya Mimura, Kathryn Bobb, et al.. (2012). Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma. Clinical Cancer Research. 18(17). 4669–4681. 66 indexed citations

16.

Vallet, Sonia, Samantha Pozzi, Kishan Patel, et al.. (2011). A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. Leukemia. 25(7). 1174–1181. 126 indexed citations

17.

Cirstea, Diana, Teru Hideshima, Scott J. Rodig, et al.. (2010). Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by Nanoparticle Albumin-Bound –Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma. Molecular Cancer Therapeutics. 9(4). 963–975. 136 indexed citations

18.

Pozzi, Sabina, Huanhuan Yan, Sonia Vallet, et al.. (2009). B203 A New Anti-Dkk-1 Antibody Targeting Myeloma Bone Disease. Clinical Lymphoma & Myeloma. 9. S111–S111. 1 indexed citations

19.

Cirstea, Diana, Teru Hideshima, Sonia Vallet, et al.. (2009). B483 A Novel Small-Molecule Inhibitor RGB 286638 Induces Apoptosis and Necrosis in Multiple Myeloma. Clinical Lymphoma & Myeloma. 9. S139–S140. 1 indexed citations

20.

Santo, Loredana, Sonia Vallet, Teru Hideshima, et al.. (2008). AT7519, a Novel Small Molecule Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma VIA GSK3β. Blood. 112(11). 251–251. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact